Cancer and Neurodegeneration: Between the Devil and the Deep Blue Sea

1. InzelbergR

JankovicJ

2007 Are Parkinson disease patients protected from some but not all cancers? Neurology 69 1542 1550

2. MollerH

MellemkjaerL

McLaughlinJK

OlsenJH

1995 Occurrence of different cancers in patients with Parkinson's disease. BMJ 310 1500 1501

3. DriverJA

LogroscinoG

BuringJE

GazianoJM

KurthT

2007 A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16 1260 1265

4. OlsenJH

FriisS

FrederiksenK

2006 Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17 582 587

5. OlsenJH

FriisS

FrederiksenK

McLaughlinJK

MellemkjaerL

2005 Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 92 201 205

6. OlsenJH

TangerudK

WermuthL

FrederiksenK

FriisS

2007 Treatment with levodopa and risk for malignant melanoma. Mov Disord 22 1252 1257

7. InzelbergR

Israeli-KornSD

2009 The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. J Neural Transm 116 1503 1507

8. FreedmanDM

TravisLB

GridleyG

KunclRW

2005 Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 25 176 180

9. BaadePD

FritschiL

FreedmanDM

2007 Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients. Neuroepidemiology 28 16 20

10. FoisAF

WottonCJ

YeatesD

TurnerMR

GoldacreMJ

2010 Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 81 215 221

11. BrainL

CroftPB

WilkinsonM

1965 Motor neurone disease as a manifestation of neoplasm (with a note on the course of classical motor neurone disease). Brain 88 479 500

12. SadotE

CarluerL

CorciaP

DelozierY

LevyC

2007 Breast cancer and motor neuron disease: clinical study of seven cases. Amyotroph Lateral Scler 8 288 291

13. NielsenNM

RostgaardK

RasmussenS

Koch-HenriksenN

StormHH

2006 Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 118 979 984

14. HjalgrimH

RasmussenS

RostgaardK

NielsenNM

Koch-HenriksenN

2004 Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 96 780 784

15. VineisP

CrosignaniP

ViganoC

FontanaA

MasalaG

2001 Lymphomas and multiple sclerosis in a multicenter case-control study. Epidemiology 12 134 135

16. MidgardR

GlattreE

GronningM

RiiseT

EdlandA

1996 Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 93 411 415

17. AndersonM

HughesB

JeffersonM

SmithWT

WaterhouseJA

1980 Gliomatous transformation and demyelinating diseases. Brain 103 603 622

18. BennettDA

LeurgansS

2010 Is there a link between cancer and Alzheimer disease? Neurology 74 100 101

19. RoeCM

FitzpatrickAL

XiongC

SiehW

KullerL

2010 Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74 106 112

20. SorensenSA

FengerK

OlsenJH

1999 Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract? Cancer 86 1342 1346

21. FialaKH

WhetteckeyJ

ManyamBV

2003 Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 9 321 327

22. ZanettiR

LoriaD

RossoS

2006 Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16 201 206

23. HernanMA

TakkoucheB

Caamano-IsornaF

Gestal-OteroJJ

2002 A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52 276 284

24. BurchellVS

GandhiS

DeasE

WoodNW

AbramovAY

2010 Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. Expert Opin Ther Targets 14 497 511

25. BurchellVS

GandhiS

DeasE

WoodNW

AbramovAY

2010 Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. Expert Opin Ther Targets 14 369 385

26. GarberJE

OffitK

2005 Hereditary cancer predisposition syndromes. J Clin Oncol 23 276 292

27. MorrisLG

VeeriahS

ChanTA

2010 Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 29 3453 3464

28. BallLG

XiaoW

2005 Molecular basis of ataxia telangiectasia and related diseases. Acta Pharmacol Sin 26 897 907

29. Gumy-PauseF

WackerP

MailletP

BettsDR

SappinoAP

2006 ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia 20 526 527; author reply 527

30. MavrouA

TsangarisGT

RomaE

KolialexiA

2008 The ATM gene and ataxia telangiectasia. Anticancer Res 28 401 405

31. BroeksA

UrbanusJH

FlooreAN

DahlerEC

KlijnJG

2000 ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 66 494 500

32. AhmedM

RahmanN

2006 ATM and breast cancer susceptibility. Oncogene 25 5906 5911

33. VogelsteinB

LaneD

LevineAJ

2000 Surfing the p53 network. Nature 408 307 310

34. BodeAM

DongZ

2004 Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4 793 805

35. DavenportCM

SevastouIG

HooperC

PocockJM

2010 Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. J Neurochem 112 552 563

36. DunysJ

SevalleJ

GiaimeE

Pardossi-PiquardR

VitekMP

2009 p53-dependent control of transactivation of the Pen2 promoter by presenilins. J Cell Sci 122 4003 4008

37. JacobsWB

KaplanDR

MillerFD

2006 The p53 family in nervous system development and disease. J Neurochem 97 1571 1584

38. EngC

2003 PTEN: one gene, many syndromes. Hum Mutat 22 183 198

39. ShilohY

RotmanG

1996 Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J Clin Immunol 16 254 260

40. KitadaT

AsakawaS

HattoriN

MatsumineH

YamamuraY

1998 Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 605 608

41. CesariR

MartinES

CalinGA

PentimalliF

BichiR

2003 Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27. Proc Natl Acad Sci U S A 100 5956 5961

42. DenisonSR

WangF

BeckerNA

SchuleB

KockN

2003 Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22 8370 8378

43. PicchioMC

MartinES

CesariR

CalinGA

YendamuriS

2004 Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10 2720 2724

44. WangF

DenisonS

LaiJP

PhilipsLA

MontoyaD

2004 Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40 85 96

45. DenisonSR

CallahanG

BeckerNA

PhillipsLA

SmithDI

2003 Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38 40 52

46. VeeriahS

TaylorBS

MengS

FangF

YilmazE

2010 Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42 77 82

47. KleinC

Lohmann-HedrichK

RogaevaE

SchlossmacherMG

LangAE

2007 Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6 652 662

48. Abou-SleimanPM

MuqitMM

McDonaldNQ

YangYX

GandhiS

2006 A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 60 414 419

49. VeeriahS

MorrisLG

SolitD

ChanTA

2010 The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2–27 that regulates cyclin E. Cell Cycle 9 1451 1452

50. ValenteEM

Abou-SleimanPM

CaputoV

MuqitMM

HarveyK

2004 Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 1158 1160

51. ZimprichA

BiskupS

LeitnerP

LichtnerP

FarrerM

2004 Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 601 607

52. Paisan-RuizC

JainS

EvansEW

GilksWP

SimonJ

2004 Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 595 600

53. GreenmanC

StephensP

SmithR

DalglieshGL

HunterC

2007 Patterns of somatic mutation in human cancer genomes. Nature 446 153 158

54. Hassin-BaerS

LaitmanY

AziziE

MolchadskiI

Galore-HaskelG

2009 The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 256 483 487

55. Saunders-PullmanR

BarrettMJ

StanleyKM

LucianoMS

ShankerV

2010 LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord 5 2536 2541

56. StrongoskyAJ

FarrerM

WszolekZK

2008 Are Parkinson disease patients protected from some but not all cancers? Neurology 71 1650; author reply 1650–1651

57. BressmanS

GiladiN

MarderK

Orr-UrtregerA

2009 Parkinson's disease, Ashkenazi Jews and LRRK2–a consortium proposal [abstract]. The Michael J Fox Foundation for Parkinson's Research searchable database of funded grants. Available: http://www.michaeljfox.org/research_MJFFfundingPortfolio_searchableAwardedGrants_3.cfm?ID=559. Accessed 22 November 2010

58. FordD

BlissJM

SwerdlowAJ

ArmstrongBK

FranceschiS

1995 Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62 377 381

59. GandiniS

SeraF

CattaruzzaMS

PasquiniP

AbeniD

2005 Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41 28 44

60. GandiniS

SeraF

CattaruzzaMS

PasquiniP

PicconiO

2005 Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41 45 60

61. GandiniS

SeraF

CattaruzzaMS

PasquiniP

ZanettiR

2005 Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41 2040 2059

62. NoeM

SchroyP

DemierreMF

BabayanR

GellerAC

2008 Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices. Cancer Causes Control 19 1 12

63. GaoX

SimonKC

HanJ

SchwarzschildMA

AscherioA

2009 Family history of melanoma and Parkinson disease risk. Neurology 73 1286 1291

64. GaoX

SimonKC

HanJ

SchwarzschildMA

AscherioA

2009 Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 65 76 82

65. TangL

LiG

TronVA

TrotterMJ

HoVC

1999 Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res 9 148 154

66. VerdaguerE

JordaEG

StrangesA

CanudasAM

JimenezA

2003 Inhibition of CDKs: a strategy for preventing kainic acid-induced apoptosis in neurons. Ann N Y Acad Sci 1010 671 674

67. AlviraD

TajesM

VerdaguerE

de ArribaSG

AllgaierC

2007 Inhibition of cyclin-dependent kinases is neuroprotective in 1-methyl-4-phenylpyridinium-induced apoptosis in neurons. Neuroscience 146 350 365

68. BishopDT

DemenaisF

IlesMM

HarlandM

TaylorJC

2009 Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41 920 925

69. FalchiM

BatailleV

HaywardNK

DuffyDL

BishopJA

2009 Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 41 915 919

70. YehI

BastianBC

2009 Genome-wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res 22 527 528

71. Paisan-RuizC

BhatiaKP

LiA

HernandezD

DavisM

2009 Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65 19 23

72. HosgoodHD3rd

MenasheI

ShenM

YeagerM

YuengerJ

2008 Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 29 1938 1943

73. GandhiS

WoodNW

2010 Genome-wide association studies: the key to unlocking neurodegeneration? Nat Neurosci 13 789 794

74. WestAB

DawsonVL

DawsonTM

2005 To die or grow: Parkinson's disease and cancer. Trends Neurosci 28 348 352

75. StaropoliJF

2008 Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 30 719 727

76. GarberK

2010 Parkinson's disease and cancer: the unexplored connection. J Natl Cancer Inst 102 371 374

77. KimRH

MakTW

2006 Tumours and tremors: how PTEN regulation underlies both. Br J Cancer 94 620 624

78. HetmanM

VashishtaA

RempalaG

2010 Neurotoxic mechanisms of DNA damage: focus on transcriptional inhibition. J Neurochem 114 1537 1549

79. FengZ

JinS

ZupnickA

HohJ

de StanchinaE

2006 p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25 1 7

80. BaeBI

XuH

IgarashiS

FujimuroM

AgrawalN

2005 p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 29 41

81. da CostaCA

CheclerF

2010 A novel parkin-mediated transcriptional function links p53 to familial Parkinson's disease. Cell Cycle 9 16 17

82. da CostaCA

SunyachC

GiaimeE

WestA

CortiO

2009 Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 11 1370 1375

83. CheclerF

DunysJ

Pardossi-PiquardR

Alves da CostaC

2010 p53 is regulated by and regulates members of the gamma-secretase complex. Neurodegener Dis 7 50 55

84. BehrensMI

LendonC

RoeCM

2009 A common biological mechanism in cancer and Alzheimer's disease? Curr Alzheimer Res 6 196 204

85. MalkinD

LiFP

StrongLC

FraumeniJFJr

NelsonCE

1990 Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 1233 1238

86. NagakuboD

TairaT

KitauraH

IkedaM

TamaiK

1997 DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231 509 513

87. BonifatiV

RizzuP

van BarenMJ

SchaapO

BreedveldGJ

2003 Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 256 259

88. Le NaourF

MisekDE

KrauseMC

DeneuxL

GiordanoTJ

2001 Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7 3328 3335

89. MacKeiganJP

ClementsCM

LichJD

PopeRM

HodY

2003 Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 63 6928 6934

90. HodY

2004 Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem 92 1221 1233

91. KimRH

PetersM

JangY

ShiW

PintilieM

2005 DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7 263 273

92. UnokiM

NakamuraY

2001 Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20 4457 4465

93. MonacoEA3rd

VallanoML

2003 Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians. Curr Med Chem 10 367 379

94. DhariwalaFA

RajadhyakshaMS

2008 An unusual member of the Cdk family: Cdk5. Cell Mol Neurobiol 28 351 369

95. Arias-VasquezA

AulchenkoYS

IsaacsA

van OosterhoutA

SleegersK

2008 Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study. J Neurol 255 655 662

96. GreggioE

SingletonA

2007 Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. Expert Rev Proteomics 4 783 792

97. MacKeiganJP

MurphyLO

BlenisJ

2005 Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7 591 600

98. CiavarellaS

MilanoA

DammaccoF

SilvestrisF

2010 Targeted therapies in cancer. BioDrugs 24 77 88

99. BajajA

DriverJA

SchernhammerES

2010 Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21 697 707

100. LeyTJ

MardisER

DingL

FultonB

McLellanMD

2008 DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 66 72

101. JonesPA

BaylinSB

2007 The epigenomics of cancer. Cell 128 683 692

102. BullingerL

ArmstrongSA

2010 HELP for AML: methylation profiling opens new avenues. Cancer Cell 17 1 3

103. MiglioreL

CoppedeF

2002 Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 512 135 153

104. PolymeropoulosMH

LavedanC

LeroyE

IdeSE

DehejiaA

1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 2045 2047

105. DevineMJ

LewisPA

2008 Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. FEBS J 275 5748 5757

106. JowaedA

SchmittI

KautO

WullnerU

2010 Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30 6355 6359

107. RamirezA

HeimbachA

GrundemannJ

StillerB

HampshireD

2006 Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 1184 1191

108. HuttonM

LendonCL

RizzuP

BakerM

FroelichS

1998 Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 Nature 393 702 705

109. HardyJ

1997 Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20 154 159

110. BaldusCD

LiyanarachchiS

MrozekK

AuerH

TannerSM

2004 Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A 101 3915 3920

111. ClevelandDW

RothsteinJD

2001 From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2 806 819

112. PasinelliP

BrownRH

2006 Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7 710 723

113. RaoAK

ZieglerYS

McLeodIX

YatesJR

NardulliAM

2008 Effects of Cu/Zn superoxide dismutase on estrogen responsiveness and oxidative stress in human breast cancer cells. Mol Endocrinol 22 1113 1124

114. 1993 A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72 971 983

115. DeasE

WoodPlun-Favreau NWH

2010 Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta E-pub ahead of print 21 August 2010

116. ShimuraH

HattoriN

KuboS

MizunoY

AsakawaS

2000 Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 302 305

117. BaumannK

MandelkowEM

BiernatJ

Piwnica-WormsH

MandelkowE

1993 Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336 417 424

118. AvrahamE

RottR

LianiE

SzargelR

EngelenderS

2007 Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem 282 12842 12850

119. FitzgeraldJC

Plun-FavreauH

2008 Emerging pathways in genetic Parkinson's disease: autosomal-recessive genes in Parkinson's disease–a common pathway? FEBS J 275 5758 5766

120. SalmenaL

CarracedoA

PandolfiPP

2008 Tenets of PTEN tumor suppression. Cell 133 403 414

121. ReilingJH

SabatiniDM

2006 Stress and mTORture signaling. Oncogene 25 6373 6383